NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 32,612 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.62, for a total transaction of $1,298,797.92.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Trading Down 1.4%

Shares of NewAmsterdam Pharma stock opened at $31.44 on Friday. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The company’s fifty day simple moving average is $35.20 and its 200-day simple moving average is $31.25. The company has a market cap of $3.56 billion, a price-to-earnings ratio of -15.34 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on NAMS shares. Stifel Nicolaus raised their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Citigroup lifted their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. The Goldman Sachs Group increased their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Finally, HC Wainwright began coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in NAMS. Farther Finance Advisors LLC lifted its stake in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the period. Mather Group LLC. acquired a new stake in NewAmsterdam Pharma in the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth about $30,000. Wolverine Asset Management LLC acquired a new position in NewAmsterdam Pharma during the 3rd quarter valued at about $69,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in NewAmsterdam Pharma by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after purchasing an additional 662 shares during the period. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.